Misreading FDA: Meeting Minutes Reality Sinks Amicus
This article was originally published in Scrip
When Amicus Therapeutics Inc. met with the FDA this past spring and again just a few weeks ago, the company walked away from both meetings thinking regulators were on board with the idea the biotech was ready to submit its new drug application (NDA) for migalastat as a treatment for Fabry disease under the agency's accelerated approval pathway, or Subpart H – a plan the firm intended to carry out in the fourth-quarter.
You may also be interested in...
US FDA recommends company start a new study of oral Fabry disease drug, to be designed using the agency's irritable bowel syndrome guidance for measuring efficacy in diarrhea.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.